Contact this trialFirst, we need to learn more about you.
MT1621 for TK2 Deficiency
Recruiting1 awardPhase 2
New York, New York
This trial is testing a new drug, MT1621, for safety and efficacy in people with a deficiency in the TK2 protein. The trial will compare measurements taken before treatment with dC/dT (a similar drug) to those taken after treatment with MT1621.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service